What Is Mounjaro?

1. Two Indications

Glycemic control. Mounjaro is an adjunct to diet and exercise to improve blood sugar in type 2 diabetes. The pediatric indication for ages 10 and older was added in December 2025.

Cardiovascular risk reduction. Added in August 2026: to reduce the risk of cardiovascular death, non-fatal heart attack, or non-fatal stroke in adults with type 2 diabetes at high risk of those events. The trial behind it, SURPASS-CVOT, is covered below.

Weight reduction is not on the label, even though the molecule produces it. Lilly sells the same drug as Zepbound for that, with its own trials. The Zepbound vs Mounjaro page explains why one molecule carries two names.

2. The Dose Ladder

Escalation is by need and tolerability, not calendar: the label says to increase in 2.5 mg increments after at least 4 weeks on the current dose if additional glycemic control is needed. The titration schedule generator dates the steps from a chosen start day.

Missed dose. Take it as soon as possible within 4 days (96 hours). Past that, skip and resume on the regular day. Never inject two doses within 3 days of each other. The day of the week can be changed as long as two doses are at least 3 days apart.

3. Pens and Vials

The current label lists three presentations, all at the same six strengths:

• A single-dose pen, one weekly dose per pen.
• A single-dose vial, drawn up with a syringe.
• A multi-dose vial or single-patient KwikPen holding four weekly doses, from 10 mg/2.4 mL for four 2.5 mg doses up to 60 mg/2.4 mL for four 15 mg doses.

A vial dose is prescribed in milligrams but drawn in millilitres, and an opened multi-dose container has a discard date. The dose calculator does the conversion and the beyond-use date calculator tracks the discard date. Injection sites are the abdomen, thigh, or back of the upper arm, rotated each dose.

4. The Evidence

SURPASS-2 randomised 1,879 adults with type 2 diabetes on metformin to tirzepatide 5, 10, or 15 mg or semaglutide 1 mg. Nausea was 17% to 22% on tirzepatide and 18% on semaglutide; clinically significant hypoglycemia was rare on both, 0.2% to 1.7% versus 0.4%. The Ozempic vs Mounjaro page charts the full comparison.

SURPASS-CVOT enrolled adults with type 2 diabetes and established cardiovascular disease and compared tirzepatide with dulaglutide, an active drug already shown to reduce events. The result establishes that tirzepatide is at least as protective as dulaglutide; it does not measure the benefit over no treatment. That distinction is why the Mounjaro indication is framed as risk reduction in people at high risk, and why the placebo-controlled trials semaglutide has, SUSTAIN-6 and FLOW, remain a point of difference.

5. Safety

The label opens with a boxed warning: tirzepatide causes thyroid C-cell tumors in rats, human relevance unknown, and Mounjaro is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Warnings cover acute pancreatitis, hypoglycemia when combined with insulin or a sulfonylurea, hypersensitivity reactions, acute kidney injury from dehydration, severe gastrointestinal reactions, diabetic retinopathy complications in people with a history of retinopathy, acute gallbladder disease, pulmonary aspiration under anesthesia, and never sharing a KwikPen.

The most common adverse reactions, at 5% or more, are nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain, mostly during escalation. Mounjaro delays gastric emptying, so people on oral hormonal contraceptives are told to switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose increase. Pregnancy: the label says it may cause fetal harm, based on animal studies.

6. Tracking It

The useful record for a weekly injection on a stepped ladder is short: product, date, milligrams, injection site, and any side effect. Because the half-life is about 5 days, a dose is still present for three to four weeks after the last injection, and a late or missed dose shows up as a gap in that curve. How GLP-1 tracking works covers what to log, and the missed-dose helper applies the 4-day rule.

7. Mounjaro FAQ

• What is Mounjaro approved for?

  As of the August 2026 label: to improve glycemic control in adults and children 10 years and older with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk. Weight reduction and sleep apnea are on the Zepbound label, not Mounjaro's.

• Does Mounjaro come in a vial?

  Yes. The current label lists a single-dose pen, a single-dose vial at each strength, and a multi-dose vial or KwikPen holding four doses. The strengths are the same in every format: 2.5 to 15 mg per weekly dose.

• What if I miss a Mounjaro dose?

  The label says to take it as soon as possible within 4 days (96 hours) of the missed dose, then continue on the regular day. If more than 4 days have passed, skip it. Never inject two doses within 3 days of each other. The missed-dose helper walks through it.

• How much weight do people lose on Mounjaro?

  In SURPASS-2, adults with type 2 diabetes lost 7.6, 9.3, and 11.2 kg on 5, 10, and 15 mg over 40 weeks, against 5.7 kg on semaglutide 1 mg. Weight reduction is not an indication on the Mounjaro label; the Zepbound trials in people without diabetes showed larger losses.

• Is Mounjaro the same as Zepbound?

  Same molecule, same doses, same devices. The labels differ: Mounjaro carries type 2 diabetes and cardiovascular indications, Zepbound carries weight reduction and obstructive sleep apnea. Coverage usually follows the label.

8. Sources